Allergan (AGN), Editas Medicine (EDIT) Enter Alliance to Discover and Develop CRISPR Genome Editing Medicines … – StreetInsider.com
|
Allergan (AGN), Editas Medicine (EDIT) Enter Alliance to Discover and Develop CRISPR Genome Editing Medicines …
StreetInsider.com The agreement covers early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine's unparalleled CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1. Editas Medicine's lead program is being … |
